News

News

February 10, 2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
February 9, 2026
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
February 5, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
January 12, 2026
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
January 7, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
January 6, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
January 5, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
December 16, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
December 2, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Investor Relations Contact
Jonathan Neely

jonathan.neely@dbv-technologies.com

Media Contact
Brett Whelan
brett.whelan@dbv-technologies.com
Subscribe to get the latest DBV press releases
Subscribe
Scroll to Top